Direct determination of zinc in plasma by graphite furnace atomic absorption spectrometry using palladium/magnesium and EDTA matrix modification with high temperature pyrolysis

BJ Stevens; DJ Hare; I Volitakis; RA Cherny; BR Roberts

Journal article

Direct determination of zinc in plasma by graphite furnace atomic absorption spectrometry using palladium/magnesium and EDTA matrix modification with high temperature pyrolysis

BJ Stevens, DJ Hare, I Volitakis, RA Cherny, BR Roberts

Journal of Analytical Atomic Spectrometry | ROYAL SOC CHEMISTRY | Published : 2017

DOI: 10.1039/c7ja00033b

Abstract

High prevalence of zinc deficiency stemming from malnutrition, gastrointestinal diseases and low dietary intake accounts for detection of zinc in plasma being a frequently requested clinical pathology assay. Serum and plasma zinc determination by graphite furnace atomic absorption spectrometry (GFAAS) has previously been hampered by significant interfering species and intolerance to high pyrolysis temperatures. In this Technical Note, we report a GFAAS method developed to overcome these restrictions by employing two matrix modifiers and a high pyrolysis temperature. Serum and plasma samples were diluted twenty times with an Antifoam/Triton-X-100 diluent and measured against aqueous standards..

View full abstract

University of Melbourne Researchers

Dominic Hare Author

Related Projects (2)

TRACING IRON FROM NEURODEVELOPMENT TO NEURODEGENERATION IN PARKINSON'S DEISEASE

Excessive brain iron can cause neurodegeneration in Parkinson's disease (PD). This project will examine a link between early-life iron expos..

Metalloproteomics: A new piece of the systems biology puzzle

Systems biology uses advanced analytical technology to study the complex chemistry of the living cell. Many cellular functions are the resul..

Grants

Awarded by Agilent Technologies

Funding Acknowledgements

We wish to thank Mr Graeme Carter and the staff of Australian Clinical Labs (Melbourne) for the measurement of plasma zinc by FAAS. Helpful advice was provided by Mr John Sanders of Varian Pty. Ltd (now Agilent Technologies), Springvale, Victoria, Australia. The Florey Institute of Neuroscience and Mental Health acknowledges the strong support from the Victorian Government and the funding from the Operational Infrastructure Support Grant. Financial support from the Cooperative Research Centre (CRC) for Mental Health (Grant ID: 20100104), an Australian Government Initiative and the Australian Research Council Linkage Projects Scheme (LP140100095, with Agilent Technologies) is acknowledged. DJH is a National Health and Medical Research Council Career Development Fellow (Grant ID: APP1122981) partly supported by Agilent Technologies.